Dehydron
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
A dehydron is an intramolecular hydrogen bond incompletely shielded from water attack, with a propensity to promote its own dehydration. Dehydrons constitute a special kind of packing defect in soluble proteins and were named and characterized by Argentine-born American scientist Ariel Fernandez, from Rice University, and his coworkers Ridgway Scott, Stephen Berry and Harold Scheraga.
Dehydrons are partially dehydrated amide-carbonyl hydrogen bonds that result from an incomplete clustering of side-chain nonpolar groups that "wrap" the polar pair within the protein structure. Dehydrons are sticky, since they promote the removal of surrounding water through protein associations and/or ligand binding. This further dehydration enhances the electrostatic interaction between the amide and carbonyl groups by de-shielding their partial charges. Furthermore, the dehydration stabilizes the hydrogen bond by destabilizing the nonbonded state that consists of dehydrated isolated charges. Hence, the name dehydron makes reference to the tendency to promote its dehydration, a process both energetically and thermodynamically favored. Thus, dehydrons are markers for protein interactivity, and hence functional indicators, and may possibly serve as drug targets.
Dehydron patterns are not conserved across paralog proteins, hence dehydrons constitute structural singularities that may be targeted by drug ligands to achieve higher specificity and ultimately, to curb side effects. This observation prompted Ariel Fernandez to introduce the design concept of "drug as dehydron wrapper", and heralded the advent of a novel approach to drug development based on the so-called wrapping technology.
Dehydrons in the news:
Redesigned gleevec overcomes drug resistance in cancer therapy:
Re-engineered gleevec curbs heart-related complications:
References:
- Fernandez, A. and Scott, L. R. Biophys. J. 85, 1914-1928 (2003).
- Fernandez, A. and Scheraga, H. A. Proc. Natl. Acad. Sci. USA 100, 113-118 (2003).
- Fernandez, A. and Scott, L. R. Phys. Rev. Lett. 91, 08102 (2003).
- Fernandez, A., Rogale, K., Scott, L. R. and Scheraga, H. A. Proc. Natl. Acad. Sci. USA 101, 11640-11645 (2004).
- Fernandez, A. and Berry, R. S. Proc. Natl. Acad. Sci. USA 101, 13460-13465 (2004).
- Fernandez, A. Nature Biotechnology 22, 1081-1085 (2004).
- Fernandez, A. Structure 13, 1829-1836 (2005).
- Fernandez A, et al. Cancer Research 67, 4028-4033 (2007) Priority Report.
- Chen, J. P., Zhang, X. and Fernandez, A. Bioinformatics 23, 563-572 (2007)
- Crespo, A. and Fernandez, A. Drug Discovery Today 12, 917-923 (2007)
- Fernandez, A. et al. Journal of Clinical Investigation 117, 4044-4054 (2007)
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
